These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26902621)

  • 21. Use of Botulinum Toxin in Urologic Diseases.
    Chermansky CJ; Chancellor MB
    Urology; 2016 May; 91():21-32. PubMed ID: 26777748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan-A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study).
    Wang CC; Chou EC; Chuang YC; Lin CC; Hsu YC; Liao CH; Kuo HC
    Toxins (Basel); 2021 Dec; 13(12):. PubMed ID: 34941748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.
    Chancellor MB; Patel V; Leng WW; Shenot PJ; Lam W; Globe DR; Loeb AL; Chapple CR
    Neurology; 2013 Aug; 81(9):841-8. PubMed ID: 23892704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Gamé X; Mouracade P; Chartier-Kastler E; Viehweger E; Moog R; Amarenco G; Denys P; De Seze M; Haab F; Karsenty G; Kerdraon J; Perrouin-Verbe B; Ruffion A; Soler JM; Saussine C
    J Pediatr Urol; 2009 Jun; 5(3):156-64. PubMed ID: 19264554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review.
    Stamm AW; Adelstein SA; Chen A; Lucioni A; Kobashi KC; Lee UJ
    J Urol; 2018 Oct; 200(4):809-814. PubMed ID: 29653162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AbobotulinumtoxinA for the treatment of overactive bladder.
    Flint R; Rantell A; Cardozo L
    Expert Opin Biol Ther; 2018 Oct; 18(10):1005-1013. PubMed ID: 30105941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding factors influencing primary treatment with intradetrusor onabotulinumtoxinA versus augmentation cystoplasty in patients with spina bifida.
    Li B; Peard LM; Zhao S; Graham MK; Adams C; Taylor AS; Thomas JC; Pope JC; Adams MC; Brock JW; Clayton DB
    Neurourol Urodyn; 2023 Aug; 42(6):1431-1436. PubMed ID: 37249147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of onobotulinumtoxinA as a therapeutic option for pediatric neurogenic detrusor overactivity.
    Peard LM; Pope JC; Dmochowski R
    Expert Rev Neurother; 2023; 23(9):763-774. PubMed ID: 37556757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
    Kim SW; Choi JH; Lee YS; Han SW; Im YJ
    Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
    Kennelly M; Dmochowski R; Schulte-Baukloh H; Ethans K; Del Popolo G; Moore C; Jenkins B; Guard S; Zheng Y; Karsenty G;
    Neurourol Urodyn; 2017 Feb; 36(2):368-375. PubMed ID: 26607743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does asymptomatic bacteriuria increase the risk of adverse events or modify the efficacy of intradetrusor onabotulinumtoxinA injections?
    Aharony S; Przydacz M; Van Ba OL; Corcos J
    Neurourol Urodyn; 2020 Jan; 39(1):203-210. PubMed ID: 31578763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intradetrusor onabotulinumtoxinA for overactive bladder.
    Jambusaria LH; Dmochowski RR
    Expert Opin Biol Ther; 2014 May; 14(5):721-7. PubMed ID: 24660999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum Toxin Type A Injection After Failure of Augmentation Enterocystoplasty Performed for Neurogenic Detrusor Overactivity: Preliminary Results of a Salvage Strategy. The ENTEROTOX Study.
    Michel F; Ciceron C; Bernuz B; Boissier R; Gaillet S; Even A; Chartier-Kastler E; Denys P; Gamé X; Ruffion A; Normand LL; Perrouin-Verbe B; Saussine C; Manunta A; Forin V; De Seze M; Grise P; Tournebise H; Schurch B; Karsenty G
    Urology; 2019 Jul; 129():43-47. PubMed ID: 30926380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chapter 6: Practical aspects of administration of onabotulinumtoxinA.
    Rovner E
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S32-7. PubMed ID: 25042141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin for the management of bladder dysfunction.
    Schurch B
    Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement.
    Palleschi G; Mosiello G; Iacovelli V; Musco S; Del Popolo G; Giannantoni A; Carbone A; Carone R; Tubaro A; De Gennaro M; Marte A; Finazzi Agrò E
    Neurourol Urodyn; 2018 Mar; 37(3):904-915. PubMed ID: 28877353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
    Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Not Available].
    Schulte-Baukloh H; Bauer R; Jost W; Wissel J; van Ophoven A
    Fortschr Neurol Psychiatr; 2019 Feb; 87(1):23-30. PubMed ID: 30508871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson's Disease or Post-Stroke.
    Hu JC; Hsu LN; Lee WC; Chuang YC; Wang HJ
    Toxins (Basel); 2023 Feb; 15(2):. PubMed ID: 36828479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.